Vilket är priset för Ergomed plc (2EM)

Priset för Ergomed plc (2EM) är $13.05

Vilket är marknadsvärdet för Ergomed plc (2EM)

Marknadsvärdet för Ergomed plc (2EM) är $695.07M

Ergomed plc (2EM) Vinst

Ergomed plc, alongside its affiliated entities, offers a comprehensive range of clinical trial services, encompassing planning, oversight, and execution, in addition to providing essential drug safety and medical information support. The company maintains an expansive global footprint, conducting operations throughout the United Kingdom, continental Europe, the Middle East, Africa, North America, Asia, and Australia. Its business is organized into two core divisions: Clinical Research Services and Pharmacovigilance. Ergomed assists pharmaceutical, biotechnology, and generic drug manufacturers by managing clinical development programs, facilitating post-market approval strategies, and delivering robust pharmacovigilance solutions. Their expertise is concentrated in several therapeutic domains, including oncology, haematology, allergy, respiratory, and neurology/CNS, with a notable specialization in the development of orphan drugs. Furthermore, they extend support services to clinical trial sites. Established in 1997, the organization originally traded as Ergomed Clinical Research Limited before rebranding as Ergomed plc in June 2014. Its corporate headquarters are situated in Guildford, United Kingdom.

År	Vinst	Ändra
Inte tillräckligt med data för de angivna datumen.

År

Vinst

Ändra

Inte tillräckligt med data för de angivna datumen.

Företag	Vinst	Skillnad i vinst	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$-4.02B	-	AU
Moderna, Inc. MRNA.US	$-3.09B	-	US
Lonza Group AG LONN.SW	-	-	CH

Företag

Vinst

Skillnad i vinst

Land

Vertex Pharmaceuticals Incorporated

VRTX.US

$5.27B

Argenx SE

ARGX.US

$1.95B

CSL Limited

CSL.AX

$-4.02B

Moderna, Inc.

MRNA.US

$-3.09B

Lonza Group AG

LONN.SW

Ergomed plc

2EM

Kategori